Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trovafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.90 |
| ▸ | POLB | P06746 | 2/20 | 0.90 |
| ▸ | XBP1 | P17861 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | HTT | P42858 | 1/20 | 0.90 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.90 |
| ▸ | RELA | Q04206 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | DPP4 | P27487 | 6/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trovafloxacin SCHEMBL9177464 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL20769811 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL13575805 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34465 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29384064 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29688441 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34466 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29711175 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL1229029 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29077777 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | BAYER INNOVATION GMBH (DE) | 2016-02-18 | — | — | US | claimed |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2014-09-25 | — | — | US | claimed |
| US-20130137670-A1 | ZWITTERION SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY | WAYNE STATE UNIVERSITY BOARD OF GOVERNORS (US) | 2013-05-30 | — | — | US | claimed |
| US-20100210604-A1 | ZWITTERION SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY | WAYNE STATE UNIVERSITY BOARD OF GOVERNORS | 2010-08-19 | — | — | US | claimed |
| WO-2008157308-A2 | A ZWITTERION SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY | WAYNE STATE UNIVERSITY BOARD OF GOVERNORS (US) | 2008-12-24 | — | — | WO | claimed |
| EP-1027885-B1 | Basic drug compositions with enhanced bioavailability | PFIZER PROD INC (US) | 2008-07-09 | — | — | EP | claimed |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2007-08-23 | — | — | US | claimed |
| EP-1408034-B1 | Use of Quinolone and Quinolizinone derivatives as chemotherapeutic agents | SCHULZ & SCHLIMBACH GBR (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1244434-B1 | USE OF CHEMOTHERAPEUTIC AGENTS | SCHULZ & SCHLIMBACH GBR (DE) | 2004-03-17 | — | — | EP | claimed |
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | BAYER INNOVATION GMBH (DE) | 2003-03-06 | — | — | US | claimed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | claimed |
| WO-1991002526-A1 | AZABICYCLO QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1991-03-07 | — | — | WO | claimed |
| US-20200383910-A1 | TOPICAL FORMULATION | TIOGA RES INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-10716754-B2 | Topical formulation | TIOGA RESEARCH, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20170290769-A1 | TOPICAL FORMULATION | TIOGA RESEARCH, INC. | 2017-10-12 | — | — | US | disclosed |
| WO-2017172603-A1 | TOPICAL FORMULATION | TIOGA RESEARCH, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-5266569-A | Azatricyclo carboxylic acids useful as anti-bacterial agents | PFIZER INC. (US) | 1993-11-30 | — | — | US | disclosed |
| US-5229396-A | Anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1991002526-A1 | AZABICYCLO QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137670-A1 | ZWITTERION SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY | SLC6A11, CA2, CACNA1F | EPHA2 2537/4885FLT4 4217/4885GSK3B 360/4885 |
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | NQO2, BROX, CYP4X1 | EPHA2 4568/4885FLT4 3088/4885GSK3B 3635/4885 |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | TYMP, TP53, MSH2 | EPHA2 937/4885FLT4 1450/4885GSK3B 4400/4885 |
| US-20170290769-A1 | TOPICAL FORMULATION | SORD, ACADVL, LOXL1 | EPHA2 4721/4885FLT4 1675/4885GSK3B 406/4885 |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | TYMP, TP53, MSH2 | EPHA2 937/4885FLT4 1450/4885GSK3B 4400/4885 |
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | TYMP, TP53, MSH2 | EPHA2 937/4885FLT4 1450/4885GSK3B 4400/4885 |
| US-20100210604-A1 | ZWITTERION SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY | SLC6A11, CA2, CACNA1F | EPHA2 2537/4885FLT4 4217/4885GSK3B 360/4885 |
| US-20200383910-A1 | TOPICAL FORMULATION | SORD, ACADVL, LOXL1 | EPHA2 4721/4885FLT4 1675/4885GSK3B 406/4885 |
| US-10716754-B2 | Topical formulation | SORD, ACADVL, LOXL1 | EPHA2 4721/4885FLT4 1675/4885GSK3B 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.